临床试验 以下为当前的临床试验。115 研究 神经科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 Natural History Study Protocol in PMM2-CDG (CDG-Ia) Rochester, Minn. Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P. HEALEY ALS Platform Trial Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients Rochester, Minn. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Rochester, Minn. The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy Rochester, Minn. The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE). Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia Rochester, Minn. The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia. Phase 2 Study of TAK-341 for Multiple System Atrophy Rochester, Minn. The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Rochester, Minn. The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts. A Study of Mood Symptoms in Epilepsy Patients Rochester, Minn. The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy. A Study to Evaluate Caregiver Connections via Technology for Patients with Alzheimer's and Other Types of Dementia Rochester, Minn. The purpose of this study is to optimize profile questionnaire and matching algorithm developed in Phase I and implement in final website design, and to determine if algorithmically matched participants have statistically significant increase in match satisfaction and self-reported sense of resiliency and quality of life over randomly matched caregivers. Pagination 临床研究 Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page 以下为当前的临床试验。115 研究 神经科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 Natural History Study Protocol in PMM2-CDG (CDG-Ia) Rochester, Minn. Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P. HEALEY ALS Platform Trial Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS. The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Rochester, Minn. The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients Rochester, Minn. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy Rochester, Minn. The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE). Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia Rochester, Minn. The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia. Phase 2 Study of TAK-341 for Multiple System Atrophy Rochester, Minn. The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Rochester, Minn. The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts. A Study of Mood Symptoms in Epilepsy Patients Rochester, Minn. The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy. A Study to Evaluate Caregiver Connections via Technology for Patients with Alzheimer's and Other Types of Dementia Rochester, Minn. The purpose of this study is to optimize profile questionnaire and matching algorithm developed in Phase I and implement in final website design, and to determine if algorithmically matched participants have statistically significant increase in match satisfaction and self-reported sense of resiliency and quality of life over randomly matched caregivers. Pagination 临床研究 Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page 申请预约 专长与排名研究 June 19, 2024 Share on: FacebookTwitterWeChatWeChatCloseWeibo 妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均在《美国新闻与世界报道》2024 - 2025 最佳神经内科和神经外科医院评选中名列前茅。 了解更多关于这一最高荣誉的信息 神经科科室首页部分概述测试与程序主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述测试与程序主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20117054 医学科室与中心 神经科